Shares of NeuroSense Therapeutics shifted sharply this week as a CEO letter dated August 13, 2026, laid bare the company's struggle to fund its most important clinical program, raising existential questions about whether this micro-cap biotech can keep its Nasdaq listing — or its drug alive. NeuroSense Has Promising Science but No Money for Its Big ALS Trial — Is a Nasdaq Delisting the Next Shoe to Drop?
Shares shifted as NeuroSense Therapeutics disclosed a brutally candid CEO letter on August 13, revealing that the tiny biotech cannot yet pay for the clinical trial that could define its future — and may lose its stock exchange listing if it doesn't act fast. The stock sits at $0.48, up 8.5% in today's session but down sharply from $1.98 over the past year, leaving investors to weigh genuine medical promise against bare-bones finances.
The Money for the Big Trial Still Isn't There. The FDA has cleared NeuroSense to enroll roughly 300 patients in a pivotal Phase 3 study of its ALS drug, but management admitted financing "has taken longer than expected."
The company is chasing pharmaceutical partners, strategic investors, grants, and other funding, hoping to attract capital that also brings "industry experience" and commercialization help.
As of December 31, 2025, NeuroSense reported just $0.2 million in cash and a $11.1 million net loss for the year. Running a 300-patient Phase 3 trial typically costs tens of millions of dollars — a gap that looks enormous relative to the company's resources.
The Clock on Nasdaq Is Ticking. On April 2, 2026, Nasdaq notified NeuroSense it had failed both the $1.00 minimum share price and the $35 million market value rules, giving it until September 29, 2026 to fix both. That is roughly six weeks away. The CEO letter disclosed a shareholder vote on August 26 to authorize a reverse stock split — essentially combining shares to inflate the per-share price — at a ratio between 1-for-4 and 1-for-40.
The current market cap is approximately $18.4 million , well below Nasdaq's floor. A reverse split can fix the price threshold but does nothing for market value.
Insiders Put Their Own Cash In — But Not Much. In April, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000, totaling $600,000 with another existing investor. That signals personal conviction but is a rounding error against the trial's funding needs.
A Canadian Drug Filing Offers a Lifeline. NeuroSense is targeting a December 2026 drug approval filing in Canada based on existing Phase 2b data, after Health Canada signaled no concerns with that timeline.
That earlier trial produced the first-ever statistically significant reduction in TDP-43 — a hallmark protein in ALS — in a controlled study. If Canada approves the drug ahead of a Phase 3, it could generate early revenue and attract partners. But approval is far from guaranteed, and shareholders face dilution, delisting risk, and a funding vacuum in the meantime.